Most Cited Articles

Epi-Drugs and Epi-miRs: Moving Beyond Current Cancer Therapies

, 2016; 16(9): 773-788.

Reza Salarinia, Amirhossein Sahebkar, Mostafa Peyvandi, Hamid Reza Mirzaei, Mahmoud Reza Jaafari, Maryam Matbou Riahi, Hamed Ebrahimnejad, Javid Sadri Nahand, Jamshid Hadjati, Mobina Ostadi Asrami, Sara Fadaei, Rasoul Salehi and Hamed Mirzaei


DOI: 10.2174/1568009616666151207110143


Targeted Delivery of Bleomycin: A Comprehensive Anticancer Review

, 2016; 16(6): 509-521.


DOI: 10.2174/1568009616666151130213910


The SCF-type E3 Ubiquitin Ligases as Cancer Targets

, 2016; 16(2): 119-129.

Kyoko Kitagawa and Masatoshi Kitagawa


DOI: 10.2174/1568009616666151112122231


Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies

, 2016; 16(9): 755-764.

Senthamil R. Selvan, John P. Dowling, William K. Kelly and Jianqing Lin


DOI: 10.2174/1568009615666151030102250


Targeting ABCB1 and ABCC1 with their Specific Inhibitor CBT-1® can Overcome Drug Resistance in Osteosarcoma

, 2016; 16(3): 261-274.

Marilù Fanelli, Claudia Maria Hattinger, Serena Vella, Elisa Tavanti, Francesca Michelacci, Beth Gudeman, Daryl Barnett, Piero Picci and Massimo Serra


DOI: 10.2174/1568009616666151106120434


Targeting Tumors with Small Molecule Peptides

, 2016; 16(6): 489-508.

Andrew G. Cheetham, Daniel Keith, Pengcheng Zhang, Ran Lin, Hao Su and Honggang Cui


DOI: 10.2174/1568009616666151130214646


Protein Knockdown Technology: Application of Ubiquitin Ligase to Cancer Therapy

, 2016; 16(2): 136-146.

Nobumichi Ohoka, Norihito Shibata, Takayuki Hattori and Mikihiko Naito


DOI: 10.2174/1568009616666151112122502


Regulation of Epithelial-Mesenchymal Transition by E3 Ubiquitin Ligases and Deubiquitinase in Cancer

, 2016; 16(2): 110-118.

Yasumichi Inoue, Yuka Itoh, Koichi Sato, Fumihiro Kawasaki, Chihiro Sumita, Takahito Tanaka, Daisuke Morishita and Hidetoshi Hayashi


DOI: 10.2174/1568009616666151112122126


S-equol, a Secondary Metabolite of Natural Anticancer Isoflavone Daidzein, Inhibits Prostate Cancer Growth In Vitro and In Vivo, Though Activating the Akt/FOXO3a Pathway

, 2016; 16(5): 455-465.

Zongliang Lu, Rui Zhou, Ya Kong, Jiajia Wang, Wanyuan Xia, Jing Guo, Jie Liu, Hailan Sun, Kai Liu, Jian Yang, Mantian Mi and Hongxia Xu


DOI: 10.2174/1568009616666151207105720


MicroRNA as Regulators of Cancer Stem Cells and Chemoresistance in Colorectal Cancer

, 2016; 16(9): 738-754.

Xiaoming Liu, Qi Fu, Yong Du, Yinxue Yang and William C. Cho


DOI: 10.2174/1568009616666151118114759


CD20-based Immunotherapy of B-cell Derived Hematologic Malignancies

, 2017; 17(5): 423-444.

Dariush Shanehbandi, Jafar Majidi*, Tohid Kazemi*, Behzad Baradaran and Leili Aghebati-Maleki


DOI: 10.2174/1568009617666170109151128


Mechanisms and Therapeutic Targets of microRNA-associated Chemoresistance in Epithelial Ovarian Cancer

, 2016; 16(5): 429-441.

Lingyun Zhang, Lubna Nadeem, Kristin Connor and Guoxiong Xu


DOI: 10.2174/1568009616666160404121105


The Novel VEGF121-VEGF165 Fusion Attenuates Angiogenesis and Drug Resistance via Targeting VEGFR2-HIF-1α-VEGF165/Lon Signaling Through PI3K-AKT-mTOR Pathway

, 2016; 16(3): 275-286.

Jui-Ling Tsai, Yu-May Lee, Chien-Yuan Pan and Alan Yueh-Luen Lee


DOI: 10.2174/156800961603160206125352


Advances in Synergistic Combinations of Chinese Herbal Medicine for the Treatment of Cancer

, 2016; 16(4): 346-356.

Xue-Qing Hu, Yang Sun, Eric Lau, Ming Zhao and Shi-Bing Su


DOI: 10.2174/1568009616666151207105851


Targeting Signaling Pathways in Chronic Lymphocytic Leukemia

, 2016; 16(8): 669-688.

Alice F. Muggen, Simar P. Singh, Rudi W. Hendriks and Anton W. Langerak


DOI: 10.2174/1568009616666160408145623


Understanding Molecular Pathways and Targets of Brachyury in Epithelial-mesenchymal Transition (EMT) in Human Cancers

, 2016; 16(7): 586-593.

Wenzhe Song and Glenda C. Gobe


DOI: 10.2174/1568009616666160328113338


Targeted Inhibition of Rictor/mTORC2 in Cancer Treatment: A New Era after Rapamycin

, 2016; 16(4): 288-304.

Zhipeng Zou, Juan Chen, Jun Yang and Xiaochun Bai


DOI: 10.2174/1568009616666151113120830


Polyphyllin II Restores Sensitization of the Resistance of PC-9/ZD Cells to Gefitinib by a Negative Regulation of the PI3K/Akt/mTOR Signaling Pathway

, 2017; 17(4): 376-385.

Ruzhen Zheng, Hao Jiang*, Jinhui Li, Xinge Liu and Hongwei Xu


DOI: 10.2174/1568009616666161213141608


miR-137 Suppresses the Phosphorylation of AKT and Improves the Dexamethasone Sensitivity in Multiple Myeloma Cells Via Targeting MITF

, 2016; 16(9): 807-817.

Benping Zhang, Ling Ma, Jia Wei, Jingyu Hu, Zichu Zhao, Youping Wang, Yan Chen and Fei Zhao


DOI: 10.2174/1568009616666160203114140


OncomicroRNAs-Mediated Tumorigenesis: Implication in Cancer Diagnosis and Targeted Therapy

, 2017; 17(1): 40-47.

Nana Zheng, Ping Yang, Zhiwei Wang and Quansheng Zhou


DOI: 10.2174/1568009616666160216130608


Webmaster Contact: info@benthamscience.org
Copyright © 2018 Bentham Science